Text mining of gene–phenotype associations reveals new phenotypic profiles of autism-associated genes

Sijie Li1,7, Ziqi Guo2,7, Jacob B. Ioffe3, Yunfei Hu3, Yi Zhen4*, Xin Zhou3,5,6*

Autism is a spectrum disorder with wide variation in type and severity of symptoms. Understanding gene–phenotype associations is vital to unravel the disease mechanisms and advance its diagnosis and treatment. To date, several databases have stored a large portion of gene–phenotype associations which are mainly obtained from genetic experiments. However, a large proportion of gene–phenotype associations are still buried in the autism-related literature and there are limited resources to investigate autism-associated gene–phenotype associations. Given the abundance of the autism-related literature, we were thus motivated to develop Autism_genepheno, a text mining pipeline to identify sentence-level mentions of autism-associated genes and phenotypes in literature through natural language processing methods. We have generated a comprehensive database of gene–phenotype associations in the last five years’ autism-related literature that can be easily updated as new literature becomes available. We have evaluated our pipeline through several different approaches, and we are able to rank and select top autism-associated genes through their unique and wide spectrum of phenotypic profiles, which could provide a unique resource for the diagnosis and treatment of autism. The data resources and the Autism_genepheno pipeline are available at: https://github.com/maiziezhoulab/Autism_genepheno.

Many human diseases are the result of a complex interplay between genotype, the set of genes that each organism carries, and the environment. Gene–phenotype association analysis plays an important role in understanding the mechanisms of different genetic diseases, however substantial gaps in our knowledge remain1–4. Autism Spectrum Disorder (ASD) is such a genetic condition with heritability estimated at close to 90%. Despite many Genome-Wide Association Studies (GWAS), known genetic effects can only account for only 24–33% of cases. For the majority of patients, the etiology is unknown. Part of the problem is that autism is a "spectrum" disorder, with wide variation in the type and severity of symptoms patients experience6,7. To date, the SFARI autism database has curated close to 1000 genes associated with autism, and this number is increasing every year8. A vast amount of gene–phenotype associations has been reported in the biomedical literature. Understanding how ASD phenotypes rise from a patient’s genetic composition is highly valuable to advance diagnosis and treatment4,9–14. Given the complexity of the condition, the number of genes implicated, and the variability of symptoms in individual patients, there is an enormous amount of literature for Autism studies. Phenotypes have been made available in several databases such as ClinVar15, Online Mendelian Inheritance in Men (OMIM)16, and the Human Phenotype Ontology (HPO)17 by many genetics experiments. Phenotype ontologies have also been developed to easily integrate and compare phenotypes among different species. There is also a recent integration of phenotype ontologies for autism: Autism Spectrum Disorder Phenotype Ontology (ASDPTO)18. Systematic extraction of gene–phenotype association from this literature is challenging. Development of automated text mining tools to extract a comprehensive database for gene–phenotype associations is therefore highly valuable and can alleviate the burden of manual curation2,19.

1Department of Informatics, University of Edinburgh, Edinburgh EH8 9AB, UK. 2Department of Energy and Power Engineering, Huazhong University of Science and Technology, Wuhan 430074, China. 3Department of Computer Science, Vanderbilt University, Nashville, TN 37235, USA. 4Department of Software and Information Systems, University of North Carolina at Charlotte, Charlotte, NC 28213, USA. 5Department of Biomedical Engineering, Vanderbilt University, Nashville, TN 37235, USA. 6Data Science Institute, Vanderbilt University, Nashville, TN 37235, USA. 7These authors contributed equally: Sijie Li and Ziqi Guo. *email: yzhen@uncc.edu; maizie.zhou@vanderbilt.edu
We were thus motivated to develop Autism_genepheno, a text mining pipeline to generate a comprehensive database of gene–phenotype associations in ASD that can be easily updated as new literature becomes available. We designed Autism_genepheno to identify sentence-level mentions of autism-associated genes and phenotypes from HPO and ASDPTO in literature through natural language processing (NLP) methods. To further determine the strength of gene–phenotype associations, we applied a measure of Normalized Pointwise Mutual Information (NPMI) on the comprehensive extracted gene–phenotype associations. We used Autism_genepheno to process the last five years of autism publications and generated a large gene–phenotype association matrix for autism-associated genes classification. We evaluated gene–phenotype associations from Autism_genepheno through comparison with existing gene–phenotype associations in reference databases. Gene Ontology (GO) analysis we performed for some specific clusters of autism-associated genes further confirmed the strength of our gene–phenotype associations. The gene classification analysis for SFARI genes also revealed specific phenotypic profiles for different classes of SFARI genes which conferred autism risk at different levels, and we were able to select the top 10% SFARI genes with the most influential roles in a genetic interaction network based on their phenotypic profiles.

**Methods**

**Pipeline overview.** We assumed a gene–phenotype association exists if gene–phenotype co-occurrence pairs were detected in the same sentence of the published articles. We introduced a pipeline to detect gene–phenotype associations of Autism Spectrum Disorder from PubMed Central (PMC) articles. The overview pipeline is shown in Fig. 1. The input of the pipeline is a corpus consisting of autism research articles in XML. The output is a list of quantitative gene–phenotype associations detected from the corpus. The pipeline includes three steps: (1) detecting sentence-level gene–phenotype associations with curated gene list and phenotype list; (2) standardizing the detected phenotypes and their top-level phenotypic category with HPO; and (3) ranking gene–phenotype associations by Normalized Pointwise Mutual Information (NPMI).

**Data resources.** We searched 15,070 autism research articles in PMC as our corpus. The search criteria were defined as including the keywords ‘Autism’ AND ‘Gene’ over the last 5 years, from 2015 to 2020. We used 19,979 genes from VariCarta, a comprehensive database of harmonized genomic variants found in autism spectrum disorder sequencing studies. Among 19,979 genes in VariCarta, we further identified 992 autism-associated genes from the SFARI database, and they were categorized into four classes (class 1: High Confidence, N = 194; class 2: Strong Candidate, N = 207; class 3: Suggestive Evidence, N = 507; class 4: Syndromic, N = 84) based on their gene scores.
We constructed a phenotype list from two sources: Autism Spectrum Disorder Phenotype Ontology (ASDPTO) and Unified Medical Language System (UMLS)[21]. The phenotype list covered 284 concepts from ASDPTO; 33,384 concepts in Human Phenotype Ontology (HPO); 31,822 concepts in Online Mendelian Inheritance in Man (OMIM), 102 concepts in Diseases Database (DDB), 208,086 concepts in the Systematized Nomenclature of Medicine- Clinical Terms (SNOMED-CT, US edition) and 56,825 concepts in the Medical Subject Headings (MSH), respectively from UMLS. We extracted the above phenotype concepts from UMLS by filtering two data files MRCONSO.RFF and MRSTY.RFF from the UMLS Metathesaurus 2020AA. The file MRCONSO.RFF includes all concepts with their concept identifier, concept names, connected languages and source vocabularies. The file MRSTY.RFF provides a semantic type for each concept. The two layer filtering includes: (1) Filtering by source vocabularies, we added the concepts from MRCONSO.RFF into the phenotype list by selecting HPO, OMIM, DDB, SNOMED-CT and MSH as the source vocabularies. (2) Filtering by semantic types, we selected the concepts from the above five source vocabularies with their corresponding semantic types. We included concepts with semantic types of T047 (Disease or Syndrome), T048 (Mental or Behavioral Dysfunction) and T184 (Sign or Symptom) for the source vocabularies OMIM, DDB, SNOMED-CT and MSH. For HPO, we included all concepts to the phenotype list excluding concepts with semantic types of T045, T077, T079, T080, T082 or T169, etc.

Detecting sentence-level gene-phenotype associations. We detected phenotype and gene information at the sentence-level from autism research articles in XML format with NLP methods. The step of detecting the sentence-level gene-phenotype associations in each article included four sub-steps: (1) process each article into sentence level with tokenizer, stop-words remover and lemmatizer; (2) tokenize and lemmatize all terms in the phenotype list that is constructed with ASDPTO and UMLS; (3) identify target sentence if at least one tokenized phenotype term from the phenotype list and one gene symbol from the gene list are mentioned in the processed sentence with sub-string match; (4) extract all mentions of phenotype and gene in target sentence. Finally, we detected the sentence-level gene-phenotype ASD association in the corpus.

Ontology based phenotype standardization. The mentions of phenotype identified in the corpus have multiple verbal expressions, synonyms and lexical variants due to human language features. We developed a source based method to standardize the mentions of phenotype in a consistent and systematic way. The source based method used the sources of the constructing phenotype list to standardize the mentions of phenotype with the most commonly preferred name in standard biomedical vocabularies. The Human Phenotype Ontology (HPO) is the highest priority source for a standard vocabulary of human phenotype. Other standard vocabularies were utilized as a complement to the HPO with the following descending priority order: ASDPTO, OMIM, DDB, SNOMED-CT and MSH. The standardization of phenotype with HPO further enabled us to group these identified phenotypes into 23 top-level phenotypic categories of phenotypic abnormality: Abnormal cellular phenotype, Abnormality of blood and blood-forming tissues, Abnormality of head or neck, Abnormality of limbs, Abnormality of metabolism/homeostasis, Abnormality of prenatal development or birth, Abnormality of the breast, Abnormality of the cardiovascular system, Abnormality of the digestive system, Abnormality of the ear, Abnormality of the endocrine system, Abnormality of the eye, Abnormality of the genitourinary system, Abnormality of the immune system, Abnormality of the integument, Abnormality of the musculoskeletal system, Abnormality of the nervous system, Abnormality of the respiratory system, Abnormality of the thoracic cavity, Abnormality of the voice, Constitutional symptom, Growth abnormality and Neoplasm. We used these top-level phenotypic categories to label autism-associated genes in the analysis that followed. If the standardized phenotype was not included in HPO, we defined its top-level phenotypic category as ‘NA’.

Ranking gene-phenotype associations. To select high-confidence gene-phenotype associations, we ranked each association between a gene and phenotype using Normalized Pointwise Mutual Information (NPMI). NPMI is a measure of association between two terms[22,23]. NPMI ranges from –1 to 1, with –1 indicating that the two terms never occurred together, 0 indicating that the terms occurrence independently, and 1 indicating that the terms always co-occurred together. In our study, the two terms are gene and phenotype. We calculate the NPMI between a gene G and a phenotype P as

\[ \text{NPMI}(G, P) = \frac{(\ln \frac{p(G,P)}{p(G)p(P)})}{(-\ln \frac{p(G,P)}{p(G)p(P)})} \]  

(1)

where \( p(G) \) and \( p(P) \) are the probability of gene and phenotype occurring in the corpus separately, and \( p(G,P) \) is the observed probability of gene and phenotype occurring in the same sentence. In our study, \( p(G) = \frac{n_G}{n_{tot}} \), where \( n_G \) is the number of sentences containing the gene, and \( n_{tot} \) is the total number of sentences in our corpus; \( p(P) = \frac{n_P}{n_{tot}} \), where \( n_P \) is the number of sentences mentioning the phenotype; \( p(G,P) = \frac{n_{G,P}}{n_{tot}} \), where \( n_{G,P} \) is the number of sentences where the gene and phenotype co-occurs. Thus, the NPMI of a gene and a phenotype is calculated by the following formula:

\[ \text{NPMI}(G, P) = \frac{(\ln \frac{n_{G,P}n_{tot}}{n_Gn_P})}{(-\ln \frac{n_{G,P}n_{tot}}{n_Gn_P})} \]  

(2)

Autism-associated gene classification by gene-phenotype associations. We constructed a gene-phenotype matrix in which each row represented a gene and each column represented a phenotype. Each entry in the matrix was set to “1” if the NPMI of the gene-phenotype association was larger than zero, and “0” if
the NPMI of the gene–phenotype association was less than or equal to zero. We then performed dimensionality reduction through t-distributed stochastic neighbor embedding (t-SNE) and Kmeans clustering for the gene–phenotype matrix, to identify different clusters of autism-associated genes.

**Evaluation metrics of clustering results.** We used four evaluation methods for clustering results, as we have described before in B limp u te ⁴ : adjusted Rand index, Jaccard index, normalized mutual information, and purity score. We used these metrics to analyze the concordance between the phenotype’s top-level phenotypic category labels and the Kmeans clustering results on the two dimensions of the t-SNE results. With the exception of the adjusted Rand index, these measurements range from 0 to 1, where 1 indicates a perfect match. Only the adjusted Rand index yields negative values, when the concordance is less than what is expected by chance. The Jaccard and Rand Index are similar measures, but the Jaccard index does not take into account pairs of elements that are in different clusters for both clusterings. The normalized mutual information integrates multiple clusterings into a single one, ignoring the original features or methods that created these clusterings. Finally, the purity score in our analysis calculates the proportion of the total number of cells that are classified correctly.

**GO analysis.** GO and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were conducted for each cluster of autism-associated genes from Kmeans clustering results through the Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.8 ² ⁵ (https://david.ncifcrf.gov/).

**Genetic interaction network graph.** We constructed a genetic interaction network graph for SFARI genes in our database for the later analysis. The nodes/vertices in this network graph were SFARI genes and an edge was added to the graph if a certain pair of nodes shared a standardized phenotype (we used the global average NPMI value as the threshold for both genes sharing the same phenotype). If multiple edges existed between two nodes, these edges were compressed (combined) and the total number of edges was treated as the weight of the compressed edge.

We used betweenness centrality to rank SFARI genes. The betweenness centrality is widely used in graph analysis as a measure of centrality based on shortest paths ² ⁶ ,² ⁷ . It is used to quantify the amount of influence a node (SFARI gene in our genetic interaction graph) has over the flow of information in a graph. The betweenness centrality calculates the shortest (weighted) path between every pair of nodes in a connected graph. Nodes (SFARI genes) will receive a higher betweenness centrality score if it most frequently lie on these shortest paths and serve as a bridge among all nodes in the graph. The betweenness centrality $C_B(v)$ for a node $v$ is defined as below:

$$C_B(v) = \sum_{s \neq v \neq t} \frac{\sigma_{st}(v)}{\sigma_{st}}$$

where $\sigma_{st}$ is the total number of shortest paths from node $s$ to node $t$ and $\sigma_{st}(v)$ is the number of those paths that pass through $v$.

**Results**

We applied Autism_genepheno to five years of literature that included the keywords autism and gene (N = 15,070), and extracted a total of 71,558 gene–phenotype associations from 6,892 autism-associated genes and 5493 standardized phenotypes (2742 from HPO, 46 from ASDPTO, 119 from OMIM, 2 from DDB, 1418 from SNOMED-CT, US edition and 1133 from MSH) (“Methods” section). Before analyzing phenotypic associations, we tested how well genes identified with this process corresponded with those identified in a well-known database of autism genomic data, SFARI Gene 3.0, which includes approximately 1,000 genes associated with autism risk. SFARI genes are categorized into four classes, associated with ASD risk at different confidence levels (“Methods” section). Our results identified gene–phenotype associations for 751 SFARI genes, of which 172 were SFARI genes labeled as class 1 (conferring highest autism risk), 154 were SFARI genes labeled as class 2, 349 were SFARI genes labeled as class 3, and 76 were SFARI genes labeled as class S. The rest 6,139 genes were not included in the SFARI autism gene database, but were included in the VariCarta autism gene database. In this paper, we labeled the rest of the genes as “NA”.

**Top mentioned genes and phenotypes in ASD.** For a general description of all genes and associations, we simply applied NPMI > 0 and $n_{G,P} > 5$ as thresholds to filter out low-confidence gene–phenotype associations. The result showed that SFARI genes accounted for 29.8% of the total percentages of genes extracted by Autism_genepheno and SFARI gene–phenotype accounted for 44.9% of the total gene–phenotype associations. Class 1 SFARI genes in particular (red bars in Fig. 2A) made up 10.6% of the genes but accounted for more than twice as many associations (24.5%). These statistics indicated that the highest-risk SFARI genes were most frequently mentioned in the context of ASD phenotype associations.

To investigate whether the most frequently mentioned genes in our data sources matched the confidence pattern observed in SFARI Gene, we plotted the top 30 genes in terms of number of papers referencing each gene. The plot in Fig. 2B shows that more than half (18) of the genes, including the top 9 genes with the highest frequencies were SFARI genes labeled with class 1 (red bars). SFARI genes labeled with class 2 (blue bars) made up the second largest group, followed by genes labeled with class 3 (green bars) and genes labeled with class S (yellow bars). This result confirmed that frequency of gene reference in the literature alone is well predictive of risk in ASD. Indeed, the SFARI Gene system integrates gene frequencies from literature mining into their scoring model.
This analysis also identified four genes (TP53, BRCA1, COMT and STAT3) not included in the most recent SFARI gene list, and thus labeled as "NA" in our plot (black bars). We were interested to investigate whether this occurrence was spurious, or reflected a hitherto unnoticed autism association. In Table 1, we randomly selected eight SFARI genes (two genes for each class label, and three high-confidence standardized phenotypes with highest NPMI values where $n_{G_p} > 5$ for each gene, respectively), and four additional "NA" genes. We evaluated all these gene–phenotype associations through the OMIM database. The TP53 gene encodes a protein called tumor protein p53 (or p53) that acts as a tumor suppressor to regulate cell division by keeping cells from growing and dividing in an uncontrolled way. The top three phenotypes extracted by AStim_genepheno for TP53 were Li-Fraumeni Syndrome, neoplasia, and cancer (Table 1). The top three phenotypes for the BRCA1 gene were ovarian cancer, breast cancer and cancer, and the top three phenotypes for the STAT3 were prostate cancer, retinoblastoma, and Buckley syndrome. The phenotypes from the three genes suggested that biological processes related to cancer could play an important role in ASD that has been missed by the SFARI database. Recent studies...
have also shown that autistic brains share gene expression and biological pathway abnormalities with cancer. The top three phenotypes for COMT gene were 22q11 microdeletion with velocardiofacial syndrome phenotype, schizophrenia, and aggression. Emerging studies also suggest that there are both clinical and biological links between autism and schizophrenia.

We also wished to test whether the most frequently mentioned standardized phenotypes in our data sources corresponded well to autism pathologies. We therefore plotted the top 30 mentioned standardized phenotypes and their respective top-level phenotypic categories (Fig. 2C). The two most commonly mentioned top-level phenotypic categories were abnormality of the nervous system and neoplasm (Fig. 2C, red and blue bars). Among other top-level phenotypic categories (Fig. 2C, green bars), the most common standardized phenotypes ordered by frequency were: (1) Child mental disorders, (2) Autism, dementia, ataxia, and loss of purposeful hand use, (3) Having too much body fat, (4) Disease of nervous system (disorder), (5) FRAXA - Fragile X syndrome, (6) Child development disorders, (7) Ganglion unspecified or myxoid cyst, (8) Diabetes, and (9) Excitability. We conclude that our pipeline identified both genes and phenotypes highly relevant for autism.

**Evaluation of gene–phenotype associations from Autism_genepheno.** To first evaluate all gene–phenotype associations extracted by the pipeline, we manually curated 50 papers to serve as a gold standard and built a metric to evaluate our results (see details in Supplementary Information). We used precision and recall metrics at the sentence, gene and phenotype level to evaluate the pipeline’s performance. The results are

| Gene     | Standardized Phenotype                                              | SFARI Class Label | NPMI |
|----------|---------------------------------------------------------------------|-------------------|------|
| FMR1     | FXTAS Fragile X Tremor Ataxia Syndrome                              | 1                 | 0.514|
| FMR1     | Mental retardation                                                  | 1                 | 0.506|
| FMR1     | FRAXA - Fragile X syndrome                                          | 1                 | 0.497|
| MECP2    | Lubs X-linked intellectual disability syndrome                      | 1                 | 0.681|
| MECP2    | Autism, Dementia, Ataxia, and Loss of Purposeful Hand Use           | 1                 | 0.572|
| MECP2    | Neonatal encephalopathy                                            | 1                 | 0.469|
| CNTNAP2  | CDFE (cortical dysplasia focal epilepsy) syndrome                  | 2                 | 0.628|
| CNTNAP2  | Language impairment                                                 | 2                 | 0.399|
| CNTNAP2  | Specific Language Disorder                                          | 2                 | 0.381|
| GRIN2A   | Acquired Aphasia with Convulsive Disorder                           | 2                 | 0.596|
| GRIN2A   | Epilepsy, Rolandic                                                  | 2                 | 0.560|
| GRIN2A   | Epilepsies, Partial                                                | 2                 | 0.445|
| DRD2     | Alcoholism                                                          | 3                 | 0.364|
| DRD2     | Addictive behavior                                                  | 3                 | 0.276|
| DRD2     | Increased body weight                                               | 3                 | 0.233|
| BRCA2    | Ovarian cancer                                                      | 3                 | 0.501|
| BRCA2    | Fanconi Anemia                                                      | 3                 | 0.439|
| BRCA2    | Breast cancer                                                       | 3                 | 0.436|
| CACNA1A  | Familial Hemiplegic Migraine                                        | S                 | 0.661|
| CACNA1A  | Ataxia 6s, Spinocerebellar                                          | S                 | 0.657|
| CACNA1A  | Hemiplegic migraine                                                 | S                 | 0.654|
| DMD      | Benign Duchenne muscular dystrophy                                  | S                 | 0.673|
| DMD      | Muscular dystrophy                                                  | S                 | 0.607|
| DMD      | BMD - Becker muscular dystrophy                                     | S                 | 0.592|
| COMT     | 22q11 microdeletion with velocardiofacial syndrome phenotype        | NA                | 0.274|
| COMT     | Schizophrenia                                                       | NA                | 0.184|
| COMT     | Aggression                                                          | NA                | 0.176|
| TP53     | Li-Fraumeni Syndrome                                                | NA                | 0.579|
| TP53     | Neoplasia                                                           | NA                | 0.317|
| TP53     | Cancer                                                              | NA                | 0.293|
| BRCA1    | Ovarian cancer                                                      | NA                | 0.550|
| BRCA1    | Breast cancer                                                       | NA                | 0.465|
| BRCA1    | Cancer                                                              | NA                | 0.339|
| STAT3    | Prostate cancer                                                     | NA                | 0.279|
| STAT3    | Retinoblastoma                                                      | NA                | 0.410|
| STAT3    | Buckley Syndrome                                                    | NA                | 0.520|

Table 1. Gene–phenotype association for eight SFARI genes and four “NA” genes. Each gene is associated with three standardized phenotypes with the highest NPMI values.
shown in Table 2. We extracted a total of 71,558 gene–phenotype associations. At the gene level, the recall and precision were approximately 91.4% and 74.4%, respectively. At the phenotype level, the recall and precision were approximately 77.1% and 98.7%, respectively. As we expected, these evaluation results suggested that genes were straightforward to detect but with a higher false positive rate, and phenotypes were intricate to detect but with a lower false positive rate. At the sentence level, recall and precision were approximately 80.3% and 71.9%, respectively.

To further evaluate the gene–phenotype associations with positive NPMI values, we used a reference annotation database from the HPO (https://hpo.jax.org/app/download/annotation). A total of 2,913 genes identified by Autism_genepheno were present in HPO. If there was at least one gene–phenotype association found both in the reference database and our autism gene–phenotype association database for each gene, we defined the autism-associated gene as a true positive (TP). A total of 94.4% (136/144) SFARI genes labeled as class 1 were evaluated as TPs, followed by 82.9% (68/82) for SFARI genes labeled as class 2, 80.1% (129/161) SFARI genes labeled as class 3, 83.3% (60/72) SFARI genes labeled as class S, and 62.4% (1531/2454) “NA” genes, not included in SFARI (Fig. 3). This evaluation result showed the SFARI class 1 genes conferring the highest autism risk had the highest true positive rate, followed by SFARI class 2 and 3 genes. The result indicates that Autism_genepheno successfully extracted gene–phenotype associations, particularly for genes with high autism risk.

**Autism-associated gene classification by top-level phenotypic categories of standardized phenotypes.** To investigate whether we could classify autism-associated genes extracted from Autism_genepheno based on gene–phenotype associations, we first generated a matrix from all the gene–phenotype associations, where each row represented a gene and each column represented a phenotype. Each entry in the matrix was set to “1” if the NPMI of the gene–phenotype association was larger than zero, and “0” if the NPMI of the gene–phenotype association was less than or equal to zero. We then applied t-SNE to this gene–phenotype matrix (see “Methods” section) and labeled genes based on their corresponding top-level phenotypic category (Fig. 4A). Since gene-to-phenotype mapping was not one-to-one but one-to-many, we selected the standardized phenotype with the highest NPMI for each gene and then obtained its top-level phenotypic category of this phenotype. Thus we only kept 3,683 autism-associated genes whose phenotypes with the highest NPMI were present in HPO since they could then be traced back to their corresponding top-level phenotypic categories. We then performed Kmeans clustering and produced seven gene clusters (Fig. 4B). The top and bottom gene clusters matched in the two scatter plots (Fig. 4A vs. B), which means that the strongest phenotypes associated with each

| Gene level | Phenotype level | Sentence level |
|------------|----------------|----------------|
| Benchmark  | 175            | 193            | 137            |
| True Positive | 160           | 148            | 110            |
| False Positive       | 55            | 2              | 43             |
| False Negative        | 15            | 44             | 27             |
| Precision           | 74.4%         | 98.7%          | 71.9%          |
| Recall              | 91.4%         | 77.1%          | 80.3%          |

**Table 2.** Gene–phenotype associations evaluation from gene, phenotype and sentence levels by manual annotations from 50 autism research articles.
gene (standardized phenotypes with the highest NPMI) was one of the main factors distinguishing different gene clusters. To quantify the concordance result of these two clusters from two different clustering and labeling sys-
tems, we evaluated it by four different metrics: adjusted Rand index, Jaccard index, normalized mutual information, and purity ("Methods" section). The adjusted Rand index, Jaccard index, normalized mutual information, and purity score achieved 0.45, 0.53, 0.53 and 0.67, respectively.

As mentioned above, the top gene cluster (genes within the black circle of the top gene group) corresponded to the neoplasm top-level phenotypic category, and the bottom gene cluster (genes within the black circle of the bottom gene group) corresponded to the abnormality of the nervous system top-level phenotypic category. We then selected genes (dots of seven different colors) within the central circle as the third gene group (Fig. 4B). These genes were classified into many different top-level phenotypic categories: abnormality of the nervous system, neoplasm, abnormality of the musculoskeletal system, abnormality of the genitourinary system, abnormality of the cardiovascular system, abnormality of the eye, and others (Fig. 4A). Even though the gene-to-phenotype mapping was one-to-many and we only chose standardized phenotypes with the highest NPMI to annotate each gene, each gene of the top and bottom groups was more likely to be associated with only one standardized phenotype. On the other hand, genes of the central group were more likely to be associated with many phenotypes. To demonstrate this, we plotted a percentage distribution of all phenotypes of genes for all three gene groups we marked in the circles (Fig. 4C). As expected, the phenotypes for the top group were dominated by the top-level phenotypic category of neoplasm (Fig. 4C, blue bars), and the phenotypes for the bottom group were dominated by the top-level phenotypic category of abnormality of the nervous system (Fig. 4C, red bars). However, the phenotypes of the central group were evenly distributed among several different upper classes (Fig. 4C, green bars). These results revealed the phenotypic pattern of autism-associated genes.

Although our analysis produced well defined clusters of genes based on associations retrieved from processing the research literature with Autism_genepheno, we wanted to ensure that these corresponded with known gene functions. We thus, performed GO analysis for genes within two clusters (Cluster 1 and 13) obtained via the Kmeans clustering results (Fig. 4B). The GO results revealed a unique and shared component for many components and pathways (N-Glycan biosynthesis, ribosome, serotonergic synapse, calcium signaling pathway, cAMP signaling pathway, and glutamatergic synapses). In every instance, the gene ontology revealed functions or pathways present in neurons, whose malfunctions were associated with the top-level phenotypic category of abnormality of the nervous system (Fig. 4D, left panel). For cluster 13, all the GO terms (such as cytokine-cytokine receptor interaction, MAPK signaling pathway, T cell receptor signaling pathway, Ras signaling pathway, prostate cancer, glioma, and melanoma) were relevant to the top-level phenotypic category of neuroplasm (Fig. 4D, right panel). These results independently confirmed that Autism_genepheno recovered phenotypes correctly.

The unique top-level phenotypic category profiles of SFARI genes and the genetic interaction network. We then wished to test if autism risk, as indicated based on SFARI gene class, correlated strongly with specific phenotypes, or top-level phenotypic categories. We thus plotted the spatial distribution of SFARI genes of different classes within the pattern of autism-associated genes identified based on phenotype. We labeled each gene from the SFARI Gene database based on its risk score, and labeled the gene as "NA" if it did not belong to the SFARI Gene database. Figure 5 shows that the 283 SFARI genes out of total 3,683 genes were spread widely in the t-SNE plot, but did not lie in the top, bottom, and central clusters which were mainly dominated by the other genes labeled as "NA" (Fig. 5A). This suggested that the phenotypic pattern of SFARI genes was highly variable and autism risk did not correlate strongly with specific phenotype clusters. To investigate the difference of phenotypic pattern for different classes of SFARI genes (class 1: 45, 2:77, 3:133 and S:28), we calculated the proportion of each class of SFARI genes belonging to each top-level phenotypic category (Fig. 5B). To calculate this, for each gene, we selected the standardized phenotype with the highest NPMI and obtained its top-level phenotypic category. This result indicated that each class of SFARI genes had some unique phenotypic pattern. First, the SFARI genes associated with high confidence level autism risk were more involved in 3 top-level phenotypic categories: abnormality of blood and blood-forming tissues, abnormality of the integument, and abnormality of head or neck. Secondly, SFARI genes labeled as class 2 in terms of autism risk were more associated with 7 top-level phenotypic categories: abnormality of limbs, abnormality of metabolism/homeostasis, abnormality of the cardiovascular system, abnormality of the digestive system, abnormality of the musculoskeletal system, abnormality of the ear, and abnormality of head or neck. Thirdly, SFARI genes labeled as class 3 in terms of autism risk were more involved in 14 top-level phenotypic categories: abnormal cellular phenotype, abnormality of blood and blood-forming tissues, abnormality of limbs, abnormality of the digestive system, abnormality of the ear, abnormality of the endocrine system, abnormality of the genitourinary system, abnormality of the immune system, abnormality of the musculoskeletal system, abnormality of the nervous system, abnormality of the respiratory system, constitutional symptom, growth abnormality and neoplasm. Lastly, the SFARI genes labeled as syndromic only contributed to a small proportion of top-level phenotypic categories, such as abnormality of metabolism/homeostasis, abnormality of the endocrine system, and abnormality of the integument.

As we saw above, SFARI genes were widely spread in the t-SNE plot and demonstrated a unique and wide spectrum of phenotypes for different classes. To further rank SFARI genes and detect the group of autism-associated genes playing important roles in connecting different genes together based on their phenotypic properties, we constructed a genetic interaction network graph (see "Methods" section). We calculated the betweenness centrality scores for all SFARI genes and selected the top 10% of SFARI genes (N = 60) with the highest betweenness centrality scores (Supplementary Table 1). The genetic interaction network graph for these 60 genes is shown in Fig. 5C, with the size of each node corresponding to its betweenness centrality score. The top 10% of nodes with the highest betweenness centrality scores included 15.9% (21/132) SFARI class 1, 8.1% (12/148) class 2, 6.3% (18/287) class 3, and 13.8% (9/65) class S genes.
Secondary analyses are also possible based on the gene–phenotype associations that are identified by Autismgenepheno. An example of relationships between language-related phenotypes and genes implicated in Autism are shown in the Supplementary material. A total of 44 phenotypes associated with language were selected from the normalized phenotype list. A total of 163 SFARI (class S, 1, 2, 3) genes for 639 gene–phenotype associations were reported in Supplementary Table 2 (MPMI> 0). The network of associations between these genes and the language-based phenotypes is shown in Supplementary Figure 1.

Discussion and conclusion
We introduce here an automatic text mining pipeline to extract gene–phenotype associations from the autism research literature. At present, gold-standard databases require substantial manual curation. Initial genetic studies identified genes mostly associated with stereotypical, syndromic autism. The condition is highly variable and multifactorial, suggesting only weak association of any given gene with a phenotype. As the publication rate accelerates and the broader spectrum of autism diagnosis is harnessed, this problem may only be compounded. Our approach integrates a comprehensive phenotype ontology list from the Autism Spectrum Disorder Phenotype Ontology and Unified Medical Language System, and a comprehensive autism-associated gene list from the VariCarta and the SFARI databases. We generated 71,558 gene–phenotype associations for a total of 6892 autism-associated genes (see Supplementary Table 3 for details). All our data resources are freely available and will be updated frequently as more autism related articles are published. Our pipeline thus provides a resource that researchers can use at any time, to obtain the most up-to-date understanding of phenotypes associated with genes implicated in autism.

To evaluate the performance of our pipeline, we manually curated 50 articles and calculated the recall and precision rates for sentence-level extraction of gene–phenotype associations (80.3% for recall and 71.9% for precision). We then used a reference database to further evaluate the performance. SFARI class 1, 2, 3, S genes and NA genes achieved true positive rates of 94.4%, 82.9%, 80.1%, 83.3%, and 62.4%, respectively. This evaluation result corresponded to the SFARI gene class/scoring system in which SFARI class 1 genes conferred the highest autism risk, followed by SFARI class 2, 3 genes. In GO analysis for specific clusters of autism-associated genes, we further confirmed that phenotypes extracted by the pipeline were consistent with biological functions and pathways.
Since the same gene could lead to different disease symptoms, Autism_genepheno generated a specialized database of autism-associated gene–phenotype associations, which were specifically mentioned in autism research, rather than a generalized database of gene–phenotype associations for all genetic studies. To investigate the phenotypic pattern of each autism-associated gene, our pipeline provides a more autism-oriented database. We were able to demonstrate the unique and wide spectrum of phenotypes for SFARI genes from the top-level phenotypic categories, and ranked the 10% SFARI genes with the most influential roles in the genetic interaction network. These results could provide a unique resource for the diagnosis and treatment for ASD.

Our pipeline has some limitations. Firstly, our approach is purely correlational. The algorithm is agnostic to disease mechanisms and causality between any association. In fact, we see our contribution as revealing non-obvious associations, particularly in those cases where no a priori evidence exists to support a mechanistic explanation. Similarly, our approach does not attempt to extract a gene dosage effect. The strength of associations we report does not map linearly to the likelihood of diagnosis or severity of symptoms. Additionally, our evaluation showed the gene–phenotype associations results contained both false positives and false negatives. False positives are caused by the following two reasons. First, due to our pipeline mistakenly identifying abbreviations as gene symbols. For instance, the pipeline identified 'CARS', the abbreviation of Childhood Autism Rating Scale, as a gene which encodes cysteinyl-tRNA synthetase (also an alias of gene CARS1). Secondly, the pipeline detected phenotype terms constructing non-phenotype noun phrases in the sentence. For example 'cancer' in the noun phrase 'National Cancer Center' was detected as the synonym of phenotypic abnormality 'Neoplasm' in HPO. Most false negatives were due to the inability to identify all possible phenotype expressions in the human language. Other false negatives come from ambiguity in processing gene symbols in non-normalized written forms. Our pipeline currently detects gene–phenotype associations in sentence-level by their co-occurrence and ranked their associations by NPMI only. The pipeline did not capture any linguistic relations between genes and phenotypes co-occurring in sentence-level, such as verbs indicating affirmation or negation. In future work, we suggest ranking gene–phenotype associations at the sentence level by capturing and quantifying their semantic relationships, such as causal relationships, declining relationships, and reinforcing relationships.

Our work relied on a method of detecting gene–phenotype association through literature mining. We demonstrated the functionality of the Autism_genepheno pipeline by mining autism related PubMed articles in the recent 5 years. In the future, we also expect to adapt our pipeline to other neurological diseases, such as Alzheimer’s disease and Schizophrenia. Our approach can thus provide a comprehensive database of gene–phenotype associations for all neurological diseases to study the phenotypic pattern of each gene in different neurological diseases and their interactions.

Received: 24 March 2021; Accepted: 6 July 2021
Published online: 27 July 2021

References
1. Young, A. I., Benonisdottr, S., Przeworski, M. & Kong, A. Deconstructing the sources of genotype-phenotype associations in humans. Science 365, 1396–1400 (2019).
2. Kafkas, Ş & Hoehndorf, R. Ontology based text mining of gene–phenotype associations: application to candidate gene prediction. Database 2019, (2019).
3. Babić, G., Martelli, P. L. & Casadio, R. Phenpath: a tool for characterizing biological functions underlying different phenotypes. BMC Genomics 20, 1–11 (2019).
4. Nisan, S. et al. Association of genes with phenotype in autism spectrum disorder. Aging (Albany NY) 11, 10742 (2019).
5. Levy, S. E., Mandell, D. S. & Schultz, R. T. Autism. Lancet 374, 1627–1638 (2009).
6. McPartland, J. & Volkmar, F. R. Autism and related disorders. Handbook Clin. Neurol. 106, 407–418 (2012).
7. Ambras, B. S. & Geschwind, D. H. Advances in autism genetics: on the threshold of a new neurobiology. Nat. Rev. Genetics 9, 341–355 (2008).
8. Ambras, B. S. et al. Sfari gene 2.0: a community-driven knowledgebase for the autism spectrum disorders (asds). Mol. Autism 4, 1–3 (2013).
9. Tager-Flusberg, H. & Joseph, R. M. Identifying neurocognitive phenotypes in autism. Philos. Trans. R. Soc. Lond. Seri. B: Biol. Sci. 358, 303–314 (2003).
10. Volkmar, F. R., State, M. & Klin, A. Autism and autism spectrum disorders: diagnostic issues for the coming decade. J. Child Psychol. Psychiatry 50, 108–115 (2009).
11. Bonnet-Brilhault, F. Genotype/phenotype correlation in autism: Genetic models and phenotypic characterization. Lencephale 37, 68–74 (2011).
12. Narita, A. et al. Clustering by phenotype and genome-wide association study in autism. Transl. Psychiatry 10, 1–12 (2020).
13. Binder, E. B. Genotype-phenotype predictions in autism: Are we there yet? (2021).
14. Wu, H. et al. Phenotype-to-genotype approach reveals head-circumference-associated genes in an autism spectrum disorder cohort. Clin. Genet. 97, 338–346 (2020).
15. Landrum, M. J. et al. Clinvar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 46, D1062–D1067 (2018).
16. Hamosh, A., Scott, A. F., Amberger, J., Valle, D. & McKusick, V. A. Online mendelian inheritance in man (omim). Hum. Mutat. 15, 57–61 (2000).
17. Robinson, P. N. et al. The human phenotype ontology: a tool for annotating and analyzing human hereditary disease. Am. J. Hum. Genetics 83, 610–615 (2008).
18. McGary, A. T., Trevett, P. & Frost, H. R. Modeling the autism spectrum disorder phenotype. Neuroinformatics 12, 291–305 (2014).
19. Baumgartner, W. A. Jr., Cohen, K. B., Fox, L. M., Acquaah-Mensah, G. & Hunter, L. Manual curation is not sufficient for annotation of genomic databases. Bioinformatics 23, 141–148 (2007).
20. Belmadani, M. et al. Varicarta: A comprehensive database of harmonized genomic variants found in autism spectrum disorder sequencing studies. Autism Res. 12, 1728–1736 (2019).
21. Bodeenreider, O. The unified medical language system (umls): integrating biomedical terminology. Nucleic Acids Res. 32, D267–D270 (2004).
22. Bouma, G. Normalized (pointwise) mutual information in collocation extraction. Proceedings of GSCL 31–40, (2009).
23. Church, K. & Hanks, P. Word association norms, mutual information, and lexicography. *Comput. Linguist.* **16**, 22–29 (1990).
24. Wen, Z.-H., Langsam, L. J., Zhang, L., Shen, W. & Zhou, X. Bimpute: A bayesian factorization method to recover single-cell rna sequencing data. *bioRxiv* https://doi.org/10.1101/2021.02.10.430649 (2021).
25. Dennis, G. *et al.* David: database for annotation, visualization, and integrated discovery. *Genome Biol.* **4**, 1–11 (2003).
26. Otte, E. & Rousseau, R. Social network analysis: a powerful strategy, also for the information sciences. *J. Info. Sci.* **28**, 441–453 (2002).
27. Park, K. & Yilmaz, A. A social network analysis approach to analyze road networks. In *ASPRS Annual Conference. San Diego, CA*, 1–6 (2010).
28. Forés-Martos, J. *et al.* Transcriptomic metaanalyses of autistic brains reveals shared gene expression and biological pathway abnormalities with cancer. *Mol. Autism* **10**, 1–16 (2019).
29. Wen, Y. & Herbert, M. R. Connecting the dots: overlaps between autism and cancer suggest possible common mechanisms regarding signaling pathways related to metabolic alterations. *Med. Hypotheses* **103**, 118–123 (2017).
30. Crespi, B. Autism and cancer risk. *Autism Res.*** **4**, 302–310 (2011).
31. De Crescenzo, F. *et al.* Autistic symptoms in schizophrenia spectrum disorders: a systematic review and meta-analysis. *Front. Psychiatry* **10**, 78 (2019).
32. Meyer, U., Feldon, J. & Dammann, O. Schizophrenia and autism: both shared and disorder-specific pathogenesis via perinatal inflammation? *Pediatr. Res.* **69**, 26–33 (2011).
33. Goldstein, G., Minsbnew, N. J., Allen, D. N. & Seaton, B. E. High-functioning autism and schizophrenia a comparison of an early and late onset neurodevelopmental disorder. *Archiv. Clin. Neuropsychol.* **17**, 461–475 (2002).

**Acknowledgements**
The authors thank the anonymous reviewers for their valuable suggestions. This work is supported by Vanderbilt University Development Funds (Grant No. FF_300033).

**Author contributions**
X.Z. and Y.Z. conceived and led this work. S.L, Z.G., Y.Z. and X.Z. designed the model and implemented the Autism_genepheno pipeline. S.L, Z.G., J.B.I., Y.H., Y.Z. and X.Z. led the data analysis. S.L, Z.G., Y.Z. and X.Z. wrote the paper with feedback from J.B.I. and Y.H.

**Competing interests**
The authors declare no competing interests.

**Additional information**
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-94742-z.

**Correspondence** and requests for materials should be addressed to Y.Z. or X.Z.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

[Creative Commons Attribution 4.0 International License](http://creativecommons.org/licenses/by/4.0/) This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/).